$HCA

More patients without insurance meant an estimated $400 million hit to HCA's income before taxes.

HCA Healthcare reported Q3 2026 revenues of $19.849B, up 3.6%, but net income fell 3.9% to $1.579B due to a $400M hit from increased uninsured patients. Adjusted EBITDA rose 1.2% to $3.918B. CEO Sam Hazen noted challenges from policy changes but expects a positive year-end. The company raised its full-year guidance to the upper half of previous estimates.

Original reporting
Published Oct 27, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HCA
Neutral
high confidence
Mentioned
$HCA
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$HCANeutralHigh
01

Why it matters

The earnings release provides fresh guidance and a quantified payer‑mix risk, likely influencing HCA's stock price and health‑care sector sentiment.

02

Market read

New guidance and payer‑mix impact constitute primary corporate news that can move HCA's share price today.

03

What to watch

Potential cost‑control measures and Medicaid supplemental payment improvements may mitigate the uninsured impact.

Relevance 8/10Novelty 8/10Timing: today

Background

HCA Healthcare reported Q3 2026 results with modest revenue growth, a 3.9% decline in net income, and a noted shift toward uninsured patients causing a $400 M pre‑tax hit. The company raised its full‑year outlook to the upper half of its prior range.

Company-level read

Ticker impact

$HCANeutralHigh confidence
Context

HCA disclosed a $400 million hit to pre‑tax income from a rise in uninsured patients and updated full‑year guidance to the upper half of its 2026 range.

Expected impact

potential short‑term pressure as market prices in the uninsured‑patient hit, but upside if guidance is viewed as better than prior expectations

Evidence & confidence

The new guidance is material and fresh, while the $400 M hit is a negative earnings component; traders may adjust positions today.

Market effects

Highlights insurance‑exchange volatility risk for hospital operators, may prompt re‑rating of health‑care sector exposure.

U.S. health‑care stocks could see heightened volatility as investors reassess payer‑mix assumptions.

Limited to U.S. health‑care sector; no broader macro impact.

Counterpoint

The guidance upgrade could outweigh the uninsured hit, offering a buying opportunity if the market overreacts to the negative payer‑mix news.

Key entities

  • HCA Healthcare, Inc.

    U.S. hospital operator reporting Q3 results and updated guidance.

Related articles

$HCAMed

BofA raises HCA Healthcare stock price target on solid execution

BofA Securities raised its price target on HCA Healthcare (NYSE:HCA) to $500 from $450, citing solid execution and upside from supplemental Medicaid programs. The company's Q3 EBITDA exceeded estimates, with revenue of $19.85B and EPS of $7.22. HCA maintained its guidance range but faces near-term headwinds. The stock trades at an EV/EBITDA of 9.6x and a P/E ratio of 14.85.

$HCAMed

HCA Healthcare Inc (HCA) Q3 2026 Earnings Call Highlights: 22 Straight Quarters

HCA Healthcare (HCA) reported Q3 2026 earnings, highlighting a 19% decline in exchange equivalent admissions, a $400M unfavorable EBITDA impact, and reduced elective surgical volumes. The company expects $550M-$650M less in Medicaid supplemental payments in 2027. HCA anticipates 2027 earnings to be generally consistent with 2026, citing exchange headwinds and reduced supplemental payments.

$HCAMedAI 8/10

What HCA Healthcare (HCA) Said on Its Q3 Earnings Call

HCA Healthcare reported $50M in incremental Medicaid benefits in Q3, raising its 2026 estimate to $600M-$800M. Costs were flat, but professional fees rose 12%. HCA reaffirmed 2026 guidance, expecting upper-half results. For 2027, it anticipates strong demand and earnings similar to 2026. The company spent $1.36B on capital expenditures, repurchased $3B in shares, and paid $165M in dividends.

$HCAHighAI 9/10

HCA (HCA) Q3 2026 Earnings Call Transcript

HCA Healthcare reported Q3 2026 revenue of $19.849 billion, up 3.6% YoY, with net income of $1.579 billion. EPS grew 4.4% to $7.27. Adjusted EBITDA rose 1.2% to $3.918 billion. Volume growth continued, but payer mix shifts impacted earnings. The company raised full-year revenue and EBITDA guidance. Management expects stable 2027 earnings despite Medicaid payment headwinds.

$HCAHighAI 8/10

HCA signals flat 2027 earnings as Medicaid payments drop; shares slide

HCA Healthcare forecasted flat 2027 earnings, citing lower Medicaid payments and rising uninsured patients, causing shares to drop over 5%. CEO Sam Hazen attributed the outlook to a fluid policy environment. Analysts expect 2027 EPS of $32.14, below the company's implied guidance. HCA's Q3 adjusted profit was $7.22 per share on revenue of $19.85 billion, beating estimates. The company expects 2026 EPS between $28.70 and $30.50 on revenue of $77.0B-$79.5B.

$HCAMedAI 8/10

HCA Healthcare, Inc. Q3 2026 Earnings Call Summary

HCA Healthcare reported Q3 2026 volume growth of 3%, driven by demand across various service lines. The company offset payer mix pressure through higher revenue per admission and improved contract collections. Elective surgical volumes faced challenges due to federal policy changes. HCA maintained flat same-facility costs despite inflation. The company anticipates 2027 earnings to be generally consistent with 2026, with 2% to 3% volume growth.